Bullous pemphigoid: From the clinic to the bench

Clinics in Dermatology

Volumn 30, Issue 1, 2012, Pages 3-16

  Di Zenzo, Giovanni ^a   della Torre, Rocco ^b   Zambruno, Giovanna ^a   Borradori, Luca ^b  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BP180 ANTIBODY; BP180 PROTEIN; BPAG1 E PROTEIN; BPAG2 PROTEIN; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DAPSONE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; RITUXIMAB; TETRACYCLINE; UNCLASSIFIED DRUG;

ARTICLE; BULLOUS PEMPHIGOID; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MODEL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; STEROID THERAPY; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; DERMATOLOGIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOCORTICOIDS; HUMANS; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 83155190191     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.03.005     Document Type: Article

References (164)

1. Lipsker D., Borradori L. 'Bullous' pemphigoid: what are you? Urgent need of definitions and diagnostic criteria. Dermatology 2010, 221:131-134.
2. Bernard P., Vaillant L., Labeille B., et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases French study group. Arch Dermatol 1995, 131:48-52.
3. Jung M., Kippes W., Messer G., et al. Increased risk of bullous pemphigoid in male and very old patients: a population based study on incidence. J Am Acad Dermatol 1999, 41:266-268.
4. Marazza G., Pham H.C., Schärer L., et al. Autoimmune bullous disease Swiss study group. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009, 161:861-868.
5. Bertram F., Bröcker E.B., Zillikens D., et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009, 7:434-440.
6. Langan S.M., Smeeth L., Hubbard R., et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008, 337:a180.
7. Waisbourd-Zinman O., Ben-Amitai D., Cohen A.D., et al. Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics. J Am Acad Dermatol 2008, 58:41-48.
8. Liu H.N., Su W.P., Rogers R.S. Clinical variants of pemphigoid. Int J Dermatol 1986, 25:17-27.
9. Korman N. Bullous pemphigoid. J Am Acad Dermatol 1987, 16:907-924.
10. Di Zenzo G., Marazza G., Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007, 23:257-288.
11. Di Zenzo G., Thoma-Uszynski S., Fontao L., et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008, 128:415-426.
12. Castanet J., Lacour J.P., Ortonne J.P. Atypical clinical forms of bullous pemphigoid. Ann Dermatol Venereol 1990, 117:73-82.
13. Salomon R.J., Briggaman R.A., Wernikoff S.Y., et al. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol 1987, 123:389-392.
14. Tran J.T., Mutasim D.F. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005, 44:942-945.
15. Ernst T.M., Marsch W.C. Develop of localized pemphigoid following radiation treatment. Dermatologica 1982, 164:73-81.
16. Borradori L., Prost C., Wolkenstein P., et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 1992, 27:863-867.
17. Callens A., Vaillant L., Machet M.C., et al. Localized atypical pemphigoid on lymphoedema following radiotherapy. Acta Derm Venereol 1993, 73:461-464.
18. Person J.R. Hydrostatic bullae and pretibial pemphigoid. Int J Dermatol 1983, 22:237-238.
19. Schmidt E., Benoit S., Brocker E.B. Bullous pemphigoid with localized umbilical involvement. Acta Derm Venereol 2009, 89:419-420.
20. Nunzi E., Rongioletti F., Parodi A., et al. Dyshidrosiform pemphigoid. J Am Acad Dermatol 1988, 19:568-569.
21. Descamps V., Flageul B., Vignon-Pennamen D., et al. Dyshidrosiform pemphigoid: report of three cases. J Am Acad Dermatol 1992, 26:651-652.
22. Farrell A.M., Kirtschig G., Dalziel K.L., et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol 1999, 140:308-312.
23. Bean S.F., Michel B., Furey N., et al. Vesicular pemphigoid. Arch Dermatol 1976, 112:1402-1404.
24. Komine M., Nashiro K., Asahina A., et al. Vesicular pemphigoid. Int J Dermatol 1992, 31:868-870.
25. Ohnishi Y., Tajima S., Ishibashi A., et al. A vesicular bullous pemphigoid with an autoantibody against plectin. Br J Dermatol 2000, 142:813-815.
26. Ueda Y., Nashiro K., Seki Y., et al. Pemphigoid vegetans. Br J Dermatol 1989, 120:449-453.
27. Poulain J.F., Carmi E., Thelu F., et al. Pigmented pemphigoid. Ann Dermatol Venereol 1999, 126:616-618.
28. Korman N.J., Woods S.G. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 1995, 133:967-971.
29. Cliff S., Holden C.A. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol 1997, 136:398-401.
30. Gengoux P., Lachapelle J.M. Pemphigoid presenting as atypical excoriated prurigo: regarding 11 cases. Dermatology 1997, 194:392-394.
31. Alonso-Llamazares J., Dietrich S.M., Gibson L.E. Bullous pemphigoid presenting as exfoliative erythroderma. J Am Acad Dermatol 1998, 39:827-830.
32. Cordel N., Courville P., Martel P., et al. Extensive erosive bullous pemphigoid: an atypical and serious clinical variant. Br J Dermatol 2002, 146:537-539.
33. Geiss Steiner J., Trueb R.M., Kerl K., et al. Ecthyma-gangrenosum-like bullous pemphigoid. Dermatology 2010, 221:142-148.
34. Stingl G., Hollubar K. Coexistence of lichen planus and bullous pemphigoid. An immunopathological study. Br J Dermatol 1975, 93:313-320.
35. Sobel S., Miller R., Shatin H. Lichen planus pemphigoides, immunofluorescence findings. Arch Dermatol 1976, 112:1280-1283.
36. Trueb R.M., Didierjean L., Fellas A., et al. Childhood bullous pemphigoid. Report of a case with characterization of the targeted antigens. J Am Acad Dermatol 1999, 40:338-344.
37. Bastuji-Garin S., Joly P., Picard-Dahan C., et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996, 132:272-276.
38. Bastuji-Garin S., Joly P., Lemordant P., et al. Risk Factors for bullous pemphigoid in the elderly. A prospective case-control study. J Invest Dermatol 2011, 131:637-643.
39. Taylor G., Venning V., Wojnarowska F., et al. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 1993, 29:181-184.
40. Kirtschig G., Chow E.T., Venning V.A., et al. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol 1996, 135:738-745.
41. Wilczek A., Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?. Int J Dermatol 2006, 45:1353-1357.
42. Shipman A.R., Cooper S., Wojnarowska F. Autoreactivity to bullous pemphigoid 180: is this the link between subepidermal blistering diseases and oral lichen planus?. Clin Exp Dermatol 2011, 36:267-269.
43. Lindelof B., Islam N., Eklund G., et al. Pemphigoid and cancer. Arch Dermatol 1990, 126:66-68.
44. Ogawa H., Sakuma M., Morioka S., et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995, 9:136-141.
45. Bourdon-Lanoy E., Roujeau J.C., Joly P., et al. Bullous pemphigoid in young patients: a retrospective study of 74 cases. Ann Dermatol Venereol 2005, 132:115-122.
46. Taghipour K., Chi C.C., Vincent A., et al. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 2010, 146:1251-1254.
47. Langan S.M., Groves R.W., West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011, 131:631-636.
48. Jedlickova H., Hlubinka M., Pavlik T., et al. Bullous pemphigoid and internal diseases-A case-control study. Eur J Dermatol 2010, 20:96-101.
49. Nielsen N.M., Frisch M., Rostgaard K., et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008, 14:823-829.
50. Langer-Gould A., Albers K.B., Van Den Eeden S.K., et al. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010, 16:855-861.
51. Leung C.L., Zheng M., Prater S.M., et al. The BPAG1 locus: Alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. J Cell Biol 2001, 154:691-697.
52. Seppanen A., Suuronen T., Hofmann S.C., et al. Distribution of collagen XVII in the human brain. Brain Res 2007, 1158:50-56.
53. Chen J., Li L., Zeng Y., et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2010, 10.1159/000315393.
54. Guo L., Degenstein L., Dowling J., et al. Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 1995, 81:233-243.
55. Vaillant L., Bernard P., Joly P., et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 1998, 134:1075-1080.
56. Joly P., Courville P., Lok C., et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology 2004, 208:16-20.
57. Magro C.M., Dyrsen M.E. The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease. J Am Acad Dermatol 2008, 59:822-833.
58. Pfaltz K., Mertz K., Rose C., et al. C3d immunohistochemistry on formalin-fixed tissue is a valuable tool in the diagnosis of bullous pemphigoid of the skin. J Cutan Pathol 2010, 37:654-658.
59. Gammon W.R., Kowalewski C., Chorzelski T.P., et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 1990, 22:664-670.
60. Vodegel R.M., Jonkman M.F., Pas H.H., et al. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004, 151:112-118.
61. De Jong M.C., Bruins S., Heeres K., et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol 1996, 132:151-157.
62. Gammon W.R., Briggaman R.A., Inman A.O., et al. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 1984, 82:139-144.
63. Zillikens D., Mascaro J.M., Rose P.A., et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997, 109:679-683.
64. Nakatani C., Muramatsu T., Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol 1998, 139:365-370.
65. Husz S., Kiss M., Molnar K., et al. Development of a system for detection of circulating antibodies against hemdesmosomal proteins in patients with bullous pemphigoid. Arch Dermatol Res 2000, 292:217-224.
66. Hata Y., Fujii Y., Tsunoda K., et al. Production of the entire extracellular domain of BP180 (type XVII collagen) by baculovirus expression. J Dermatol Sci 2000, 23:183-190.
67. Kobayashi M., Amagai M., Kuroda-Kinoshita K., et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002, 30:224-232.
68. Hofmann S., Thoma-Uszynski S., Hunziker T., et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002, 119:1065-1073.
69. Sakuma-Oyama Y., Powell A.M., Oyama N., et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol 2004, 151:126-131.
70. Mariotti F., Grosso F., Terracina M., et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004, 151:1004-1010.
71. Thoma-Uszynski S., Uter W., Schwietzke S., et al. BP230- and BP180 specific autoantibodies in bullous pemphigoid. J Invest Dermatol 2004, 122:1413-1422.
72. Kromminga A., Sitaru C., Hagel C., et al. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004, 111:146-152.
73. Tsuji-Abe Y., Akiyama M., Yamanaka Y., et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005, 37:145-149.
74. Yoshida M., Hamada T., Amagai M., et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006, 41:21-30.
75. Sitaru C., Dähnrich C., Probst C., et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007, 16:770-777.
76. Feng S., Lin L., Jin P., et al. Role of BP180NC16a-enzyme-linked immunosorbent assay (ELISA) in the diagnosis of bullous pemphigoid in China. Int J Dermatol 2008, 47:24-28.
77. Tampoia M., Lattanzi V., Zucano A., et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci 2009, 1173:15-20.
78. Charneux J., Lorin J., Vitry F., et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011, 147:286-291.
79. Roussel A., Benichou J., Randriamanantany Z.A., et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011, 147:293-298.
80. Bernard P., Reguiai Z., Tancrède-Bohin E., et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009, 145:537-542.
81. Roujeau J.C., Lok C., Bastuji-Garin S., et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998, 134:465-469.
82. Colbert R.L., Allen D.M., Eastwood D., et al. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004, 122:1091-1095.
83. Rzany B., Partscht K., Jung M., et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002, 138:903-908.
84. Joly P., Benichou J., Lok C., et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005, 141:691-698.
85. Bernard P., Enginger V., Venot J., et al. [Survival prognosis in pemphigoid. A cohort analysis of 78 patients]. Ann Dermatol Venereol 1995, 122:751-757.
86. Garcia-Doval I., Conde Taboada A., Cruces Prado M.J. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 2005, 124:666-667.
87. Korman N.J. New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 2000, 18:127-137.
88. Laffitte E., Borradori L. Fiche thérapeutique: prise en charge de la pemphigoïde bulleuse. Ann Dermatol Venerol 2001, 128:677-680.
89. Joly P., Roujeau J.C., Benichou J., et al. Bullous Diseases French Study Group: a comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
90. Joly P., Roujeau J.C., Benichou J., et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009, 129:1681-1687.
91. Morel P., Guillaume J.C. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol 1984, 111:925-928.
92. Dreno B., Sassolas B., Lacour P., et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 1993, 120:518-521.
93. Burton J.L., Harman R.M., Peachey R.D., et al. A controlled trial of azathioprine in the treatment of pemphigoid [proceedings]. Br J Dermatol 1978, 99:14.
94. Guillaume J.C., Vaillant L., Bernard P., et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993, 129:49-53.
95. Beissert S., Werfel T., Frieling U., et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007, 143:1536-1542.
96. Venning V.A., Millard P.R., Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989, 120:83-92.
97. Fivenson D.P., Breneman D.L., Rosen G.B., et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994, 6:753-758.
98. Reguiaï Z., Tchen T., Perceau G., et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol 2009, 136:431-434.
99. Haase C., Büdinger L., Borradori L., et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998, 110:282-286.
100. Schmidt E., Obe K., Brocker E.B., et al. Serum levels of autoantibdies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000, 136:174-178.
101. Borradori L., Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 1999, 112:411-418.
102. Giudice G.J., Squiquera H.L., Elias P.M., et al. Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest 1991, 87:734-738.
103. Hopkinson S.B., Riddelle K.S., Jones J.C.R. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J Invest Dermatol 1992, 99:264-270.
104. Jonkman M.F., de Jong M.C., Heeres K., et al. 180-kD bullous pemphigoid antigen (BP180) is deficient in generalized atrophic benign epidermolysis bullosa. J Clin Invest 1995, 95:1345-1352.
105. McGrath J.A., Gatalica B., Christiano A.M., et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nature Genet 1995, 11:83-86.
106. Stanley J.R., Tanaka T., Mueller S., et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 1988, 82:1864-1870.
107. Sawamura D., Li K., Chu M.L., et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 1991, 266:17784-17790.
108. Green K.J., Virata M.L.A., Elgart G.W., et al. Comparative structural analysis of desmoplakin, bullous pemphigoid antigen and plectin: members of a new gene family involved in organization of intermediate filaments. Int J Biol Macromol 1992, 14:145-153.
109. Groves R.W., Liu L., Dopping-Hepenstal P.J., et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010, 130:1551-1557.
110. Diaz L.A., Ratrie H., Saunders W.S., et al. Isolation of a human epidermal cDNA corresponding to the 180-kDa autoantigen recognized by bullous pemphigoid and herpes gestationis sera. J Clin Invest 1990, 86:1088-1094.
111. Giudice G.J., Emery D.J., Zelickson B.D., et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993, 151:5742-5750.
112. Giudice G.J., Wilske K.C., Anhalt G.J., et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994, 102:878-881.
113. Perriard J., Jaunin F., Favre B., et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domain of the BP antigen 180. J Invest Dermatol 1999, 112:141-147.
114. Nie Z., Hashimoto T. IgA antibodies of cicatricial pemphigoid sera specifically react with terminus of BP180. J Invest Dermatol 1999, 112:254-255.
115. Egan C.A., Taylor T.B., Meyer L.J., et al. Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain. J Invest Dermatol 1999, 112:148-152.
116. Schumann H., Baetge J., Tasanen K., et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000, 156:685-695.
117. Egan C.A., Reddy D., Nie Z., et al. IgG anti-LABD97 antibodies in bullous pemphigoid patients' sera react with the mid-portion of the BPAg2 ectodomain. J Invest Dermatol 2001, 116:348-350.
118. Di Zenzo G., Grosso F., Terracina M., et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004, 122:103-110.
119. Thoma-Uszynski S., Uter W., Schwietzke S., et al. Auto-reactive T and B cells from bullous pemphigoid (BP) patients recognize similar antigenic regions of BP180 and BP230. J Immunol 2006, 176:2015-2023.
120. Skaria M., Jaunin F., Hunziker T., et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH-terminus of BP230. J Invest Dermatol 2000, 114:998-1004.
121. Hamada T., Nagata Y., Tomita M., et al. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule. Exp Dermatol 2001, 10:256-263.
122. Tanaka M., Hashimoto T., Amagai M., et al. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 1991, 97:725-728.
123. Miller J.E., Rico J.M., Hall R.P. IgG antibodies from patients with bullous pemphigoid bind to fusion proteins encoded by BPAg1 cDNA. J Invest Dermatol 1993, 101:779-782.
124. Ide A., Hashimoto T., Amagai M., et al. Detection of autoantibodies against the bullous pemphigoid and pemphigus antigens by an enzyme-linked immunosorbent assay using the bacterial recombinant proteins. Exp Dermatol 1995, 5:112-116.
125. Gaucherand M., Nicolas J.F., Paranhos Baccala G., et al. Major antigenic epitopes of bullous pemphigoid 230 kDa antigen map within the C-terminal end of the protein. Evidence using a 55 kDa recombinant protein. Br J Dermatol 1995, 132:190-196.
126. Ghohestani R.F., Cozzani E., Delaporte E., et al. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol 1998, 18:202-209.
127. Christophoridis S., Budinger L., Borradori L., et al. IgG, IgA and IgE antibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol 2000, 143:349-355.
128. Fairley J.A., Fu C.L., Giudice G.J. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 2005, 125:467-472.
129. Messingham K.A., Noe M.H., Chapman M.A., et al. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 2009, 346:18-25.
130. Dresow S.K., Sitaru C., Recke A., et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009, 160:429-432.
131. Büdinger L., Borradori L., Yee C., et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998, 102:2082-2089.
132. Lin MS, Gharia MA, Swartz SJ, et al. Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol 1999, 162:4991-4997.
133. Delgado J.C., Turbay D., Yunis E.J., et al. A common major histocompatibility complex class II allele HLA-DQB1*0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci 1996, 93:8569-8571.
134. Romagnani S. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Appl Immunol 1992, 98:279-285.
135. Bernard P., Aucouturier P., Denis F., et al. Immunoblot analysis of IgG subclass of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopath 1990, 54:484-494.
136. D'Auria L., Cordiali Fei P., Ameglio F. Cytokines and bullous pemphigoid. Eur Cytokine Netw 1999, 10:123-134.
137. Liu Z., Diaz L.A., Troy J.L., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993, 92:2480-2488.
138. Liu Z., Giudice G.J., Swartz S.J., et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995, 95:1539-1544.
139. Liu Z., Giudice G.J., Zhou X., et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997, 100:1256-1263.
140. Liu Z., Shipley J.M., Vu T.H., et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998, 188:475-482.
141. Liu Z., Shapiro S.D., Zhou X., et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000, 105:113-123.
142. Liu Z., Zhou X., Shapiro S.D., et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000, 102:647-655.
143. Liu Z., Li N., Diaz L.A., et al. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005, 115:879-887.
144. Liu Z., Sui W., Zhao M., et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008, 31:331-338.
145. Yamamoto K., Inoue N., Masuda R., et al. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol 2002, 118:485-492.
146. Nishie W., Sawamura D., Goto M., et al. Humanization of autoantigen. Nat Med 2007, 13:378-383.
147. Nishie W., Sawamura D., Natsuga K., et al. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J Immunol 2009, 183:4088-4093.
148. Gammon W.R., Inman A.O., Wheeler C.E. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods. J Invest Dermatol 1984, 83:57-61.
149. Stahle-Bäckdahl M., Inoue M., Giudice G.J., et al. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180 kD in bullous pemphigoid autoantigen. J Clin Invest 1994, 93:2022-2030.
150. Verraes S., Hornebeck W., Polette M., et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001, 117:1091-1096.
151. Shimanovich I., Mihai S., Oostingh G.J., et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004, 204:519-527.
152. Nelson K.C., Zhao M., Schroeder P.R., et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest 2006, 116:2892-2900.
153. Chen R., Ning G., Zhao M.L., et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001, 108:1151-1158.
154. Chen R., Fairley J.A., Zhao M.L., et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophilinfiltration depends on mast cell activation. J Immunol 2002, 169:3987-3992.
155. Sitaru C., Schmidt E., Petermann S., et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002, 118:664-671.
156. Zhao M., Trimbeger M.E., Li N., et al. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 2006, 177:3398-3405.
157. Dimson O.G., Giudice G.J., Fu C.L., et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003, 120:784-788.
158. Fairley J.A., Burnett C.T., Fu C.L., et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007, 127:2605-2611.
159. Zone J.J., Taylor T., Hull C., et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007, 127:1167-1174.
160. Hall R.P., Murray J.C., McCord M.M., et al. Rabbits immunized with a peptide encoded for by the 230-kd bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993, 101:9-14.
161. Kiss M., Husz S., Janossy T., et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005, 24:1-10.
162. Di Zenzo G., Calabresi V., Olasz E.B., et al. Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. J Invest Dermatol 2010, 130:1040-1047.
163. Olasz E.B., Roh J., Yee C.L., et al. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol 2007, 127:2807-2817.
164. Ujiie H., Shibaki A., Nishie W., et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010, 184:2166-2174.